TranS1, Inc.
Rick Randall, President & CEO

Is the President and CEO of TranS1, Inc, (NASDAQ:TSON) a company dedicated to developing and marketing minimally invasive therapies to treat lower back pain. Rick joined TranS1 as its first employee in 2002. Mr. Randall served as President and CEO of Innovasive Devices, Inc (NASDAQ: IDEA) from 1994 to 2000, when the firm was acquired by the Ethicon Division of Johnson & Johnson. Innovasive Devices was a developer, manufacturer and marketer of arthroscopic surgical products. From 1989 to 1996 Mr. Randall served as CEO, Chairman and Director of Target Therapeutics, Inc. (NASDAQ: TGET), a medical device company serving the interventional neurosurgery market. Target was acquired by Boston Scientific, Inc in 1997. Prior to Target, Mr. Randall held various sales and marketing management positions with Trimedyne, Inc., Baxter Edwards and the USCI Division of C.R. Bard, Inc. Mr. Randall is also co-founder of Conceptus, Inc. and Cardima, Inc. Mr. Randall is currently a Director of AbbeyMoor Medical and Salient Surgical Technologies, Inc. Mr, Randall earned a Bachelor of Science degree from State University College at Buffalo, Buffalo, NY.